Harpoon Therapeutics Inc

Harpoon Therapeutics Inc is a clinical-stage immunotherapy company focused on developing novel T cell engager therapies. Its primary aim is to create innovative treatments for patients suffering from various forms of cancer, working to advance candidates globally. Operating in the biotechnology sector, Harpoon Therapeutics Inc specialises in harnessing the immune system to fight disease. It utilises proprietary platforms to create therapies designed to direct T cells to target and kill malignant cells, aiming for improved patient outcomes in oncology. Its product pipeline includes HPN424, HPN536 and HPN217. Add this stock to your eToro watchlist to receive news and updates on the HARP share price. This content was generated by artificial intelligence. We cannot guarantee the accuracy, completeness, or timeliness of the information provided.